ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00051116
Recruitment Status : Completed
First Posted : January 7, 2003
Last Update Posted : September 23, 2009
Sponsor:
Information provided by:
Celgene

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : October 2006
  Actual Study Completion Date : October 2006